公开(公告)号：US10668126B2

公开(公告)日：2020-06-02

申请号：US11061932

申请日：2005-02-21

申请人： Ian S. Zagon ,  Patricia J. McLaughlin ,  Jill P. Smith

发明人： Ian S. Zagon ,  Patricia J. McLaughlin ,  Jill P. Smith

IPC分类号： A61K8/00 ,  A61K9/00 ,  A61K38/08 ,  A61K31/00 ,  A61K31/138 ,  A61K31/337 ,  A61K31/4745 ,  A61K31/505 ,  A61K31/525 ,  A61K31/573 ,  A61K31/66 ,  A61K31/663 ,  A61K31/704 ,  A61K31/7048 ,  A61K31/7072 ,  A61K31/7076 ,  A61K41/00 ,  A61K45/06 ,  A61K38/33 ,  A61K31/282 ,  A61K31/513 ,  A61K31/7068 ,  A61K51/00 ,  A61N5/10

摘要： The present invention relates to pharmaceutical compositions for treating neoplasias in an animal or human comprised of a carrier and therapeutically effective amounts of at least one chemotherapeutic agent along with the biotherapeutic endogenous pentapeptide Met-enkephalin, referred to as opioid growth factor. Also provided are methods of treating neoplasias in an animal or human in need of such treatment, comprising the administration to the animal or human therapeutically effective amounts of a pharmaceutical composition comprised of a carrier and therapeutically effective amounts of at least one neoplasia-treating agent, such as a chemotherapeutic agent or radiation, along with opioid growth factor.

公开(公告)号：US08003630B2

公开(公告)日：2011-08-23

申请号：US11510682

申请日：2006-08-25

申请人： Ian S. Zagon ,  Patricia J. McLaughlin ,  Jill P. Smith

发明人： Ian S. Zagon ,  Patricia J. McLaughlin ,  Jill P. Smith

IPC分类号： A61K51/00 ,  A61K33/24 ,  A61K31/70 ,  A61K31/66 ,  A01N43/04 ,  A01N57/10

CPC分类号： A61K38/08 ,  A61K31/00 ,  A61K31/138 ,  A61K31/282 ,  A61K31/337 ,  A61K31/4745 ,  A61K31/505 ,  A61K31/513 ,  A61K31/525 ,  A61K31/573 ,  A61K31/66 ,  A61K31/663 ,  A61K31/704 ,  A61K31/7048 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/7076 ,  A61K38/33 ,  A61K41/00 ,  A61K45/06 ,  A61K51/00 ,  A61N5/10 ,  A61K2300/00

摘要： The present invention relates to pharmaceutical compositions for treating neoplasias in an animal or human comprised of a carrier and therapeutically effective amounts of at least one chemotherapeutic agent along with the biotherapeutic endogenous pentapeptide Met-enkephalin, referred to as opioid growth factor. Also provided are methods of treating neoplasias in an animal or human in need of such treatment, comprising the administration to the animal or human therapeutically effective amounts of a pharmaceutical composition comprised of a carrier and therapeutically effective amounts of at least one neoplasia-treating agent, such as a chemotherapeutic agent or radiation, along with opioid growth factor.

摘要翻译： 本发明涉及用于治疗动物或人类肿瘤的药物组合物，其包含载体和治疗有效量的至少一种化学治疗剂以及生物治疗性内源五肽Met-脑啡肽，称为阿片样生长因子。 还提供了在需要这种治疗的动物或人中治疗肿瘤的方法，包括向动物或人施用治疗有效量的由载体和治疗有效量的至少一种瘤形成治疗剂组成的药物组合物， 如化疗剂或辐射，以及阿片样生长因子。

公开(公告)号：US06737397B1

公开(公告)日：2004-05-18

申请号：US09640622

申请日：2000-08-17

申请人： Ian S. Zagon ,  Patricia J. McLaughlin ,  Jill P. Smith

发明人： Ian S. Zagon ,  Patricia J. McLaughlin ,  Jill P. Smith

IPC分类号： A61K3800

CPC分类号： A61K45/06 ,  A61K31/485 ,  A61K33/24 ,  A61K38/33 ,  A61K2300/00

摘要： The present invention is related to the treatment and prevention of cancer including particularly gastrointestinal cancer. More specifically, the present invention describes the use of naltrexone, naloxone and the pentapeptide growth factor [Met5]-enkephalin to inhibit and arrest the growth of cancer. Such efficiency has been discovered to be a consequence of the functional manipulation of the zeta (&zgr;) opioid receptor through endogenous [Met5]-enkephalin. This receptor has been determined to be present in growing cancers such as pancreatic and colon cancer, for example.

摘要翻译： 本发明涉及特别是胃肠癌的癌症的治疗和预防。 更具体地，本发明描述了纳曲酮，纳洛酮和五肽生长因子[Met 5] - 脑啡肽抑制和阻止癌症生长的用途。 已经发现这种效率是通过内源[Met 5]脑啡肽对ζ（ζ）阿片受体的功能操作的结果。 已确定该受体存在于生长中的癌症例如胰腺癌和结肠癌中。

公开(公告)号：US07879870B2

公开(公告)日：2011-02-01

申请号：US11735548

申请日：2007-04-16

申请人： Jill P. Smith ,  Ian S. Zagon ,  Moshe Rogosnitzky

发明人： Jill P. Smith ,  Ian S. Zagon ,  Moshe Rogosnitzky

IPC分类号： A61K31/485

CPC分类号： A61K31/4748 ,  A61K31/485

摘要： Methods for the treatment of inflammatory and ulcerative diseases of the bowel (e.g., Crohn's disease and ulcerative colitis) with a therapeutically effective dose less than 50 mg. of opioid antagonists (e.g., naltrexone, nalmefene or naloxone) are disclosed. An embodiment of the invention includes a method of pharmaceutical treatment comprising orally administering to a human subject having Crohn's disease or ulcerative colitis a therapeutic pharmaceutical composition once per day in the evening or at bedtime, wherein the pharmaceutical composition comprises form about 3 mg to about 4.5 mg of naltrexone, nalmefene, naloxone, or a hydrochloride salt thereof in an immediate release solid dosage formulation.

摘要翻译： 用于治疗肠道炎症和溃疡性疾病（例如克罗恩病和溃疡性结肠炎）的治疗有效剂量小于50mg的方法。 的阿片样物质拮抗剂（例如纳曲酮，纳美芬或纳洛酮）。 本发明的一个实施方案包括一种药物治疗方法，其包括在晚上或在睡前每天一次口服给予具有克罗恩病或溃疡性结肠炎的人受试者治疗药物组合物，其中所述药物组合物包含约3mg至约4.5 毫克纳曲酮，纳美芬，纳洛酮或其盐酸盐。

公开(公告)号：US09149544B2

公开(公告)日：2015-10-06

申请号：US12941719

申请日：2010-11-08

申请人： Thomas T. Morgan ,  Brian M. Barth ,  James H. Adair ,  Rahul Sharma ,  Mark Kester ,  Sriram S. Shanmugavelandy ,  Jill P. Smith ,  Erhan I. Altinoglu ,  Gail L. Matters ,  James M. Kaiser ,  Christopher McGovern

发明人： Thomas T. Morgan ,  Brian M. Barth ,  James H. Adair ,  Rahul Sharma ,  Mark Kester ,  Sriram S. Shanmugavelandy ,  Jill P. Smith ,  Erhan I. Altinoglu ,  Gail L. Matters ,  James M. Kaiser ,  Christopher McGovern

IPC分类号： A61K49/00 ,  A61K41/00 ,  A61K47/48

CPC分类号： A61K49/0093 ,  A61K41/0057 ,  A61K47/48861 ,  A61K47/6923 ,  A61K49/0034 ,  A61K49/0043

摘要： Non-aggregating resorbable calcium phosphosilicate nanoparticles (CPNPs) are bioconjugated to targeting molecules that are specific for particular cells. The CPNPs are stable particles at normal physiological pH. Chemotherapy and imaging agents may be integrally formed with the CPNPs so that they are compartmentalized within the CPNPs. In this manner, the agents are protected from interaction with the environment at normal physiological pH. However, once the CPNPs have been taken up, at intracellular pH, the CPNPs dissolve releasing the agent. Thus, chemotherapeutic or imaging agents are delivered to specific cells and permit the treatment and/or imaging of those cells. Use of the bioconjugated CPNPs both limits the amount of systemic exposure to the agent and delivers a higher concentration of the agent to the cell. The methods and principals of bioconjugating CPNPs are taught by examples of bioconjugation of targeting molecules for breast cancer, pancreatic cancer, and leukemia.

摘要翻译： 非聚集的可再吸收的磷酸钙纳米粒子（CPNP）被生物缀合成靶向特定细胞特异性的分子。 CPNPs在正常生理pH下是稳定的颗粒。 化疗和成像剂可以与CPNP整体形成，使得它们在CPNP内被分隔。 以这种方式，保护试剂免于在正常生理pH下与环境的相互作用。 然而，一旦CPNP被摄取，在细胞内的pH值下，CPNP溶解释放药剂。 因此，化学治疗或显像剂被递送到特定的细胞并允许这些细胞的治疗和/或成像。 使用生物共轭CPNP都限制了全身暴露于药剂的量，并将更高浓度的药剂递送至细胞。 生物缀合CPNP的方法和原理通过乳腺癌，胰腺癌和白血病靶向分子的生物缀合的实例来教导。

公开(公告)号：US20160168246A1

公开(公告)日：2016-06-16

申请号：US14474284

申请日：2014-09-01

申请人： Jill P. Smith

发明人： Jill P. Smith

IPC分类号： C07K16/28 ,  C07K16/30 ,  A61K45/06 ,  A61K39/395

CPC分类号： C07K16/28 ,  A61K39/3955 ,  A61K45/06 ,  C07K16/2869 ,  C07K16/303 ,  C07K2317/11 ,  C07K2317/33 ,  C07K2317/34 ,  G01N33/57438 ,  G01N33/57446 ,  G01N2333/72

摘要： Human pancreatic cancer cells possess a distinct plasma membrane CCK receptor variant that can be differentiated from the classic CCK-B receptor with selective monoclonal antibodies. Use of this receptor may be helpful in early detection or treatment of patients with pancreatic cancer.

摘要翻译： 人胰腺癌细胞具有独特的质膜CCK受体变体，其可以与选择性单克隆抗体与经典的CCK-B受体区分开来。 使用此受体可能有助于早期检测或治疗胰腺癌患者。

公开(公告)号：US20110129413A1

公开(公告)日：2011-06-02

申请号：US12941719

申请日：2010-11-08

申请人： Thomas T. Morgan ,  Brian M. Barth ,  James H. Adair ,  Rahul Sharma ,  Mark Kester ,  Sriram S. Shanmugavelandy ,  Jill P. Smith ,  Erhan I. Altinoglu ,  Gail L. Matters ,  James M. Kaiser ,  Christopher McGovern

发明人： Thomas T. Morgan ,  Brian M. Barth ,  James H. Adair ,  Rahul Sharma ,  Mark Kester ,  Sriram S. Shanmugavelandy ,  Jill P. Smith ,  Erhan I. Altinoglu ,  Gail L. Matters ,  James M. Kaiser ,  Christopher McGovern

IPC分类号： A61K51/12 ,  C07K14/77 ,  C07K16/00 ,  C07K2/00 ,  C07K7/06 ,  A61K49/00 ,  A61K47/42 ,  A61K47/22 ,  A61K49/18 ,  A61K9/14 ,  B82Y5/00 ,  B82Y40/00

CPC分类号： A61K49/0093 ,  A61K41/0057 ,  A61K47/48861 ,  A61K47/6923 ,  A61K49/0034 ,  A61K49/0043

摘要： Non-aggregating resorbable calcium phosphosilicate nanoparticles (CPNPs) are bioconjugated to targeting molecules that are specific for particular cells. The CPNPs are stable particles at normal physiological pH. Chemotherapy and imaging agents may be integrally formed with the CPNPs so that they are compartmentalized within the CPNPs. In this manner, the agents are protected from interaction with the environment at normal physiological pH. However, once the CPNPs have been taken up, at intracellular pH, the CPNPs dissolve releasing the agent. Thus, chemotherapeutic or imaging agents are delivered to specific cells and permit the treatment and/or imaging of those cells. Use of the bioconjugated CPNPs both limits the amount of systemic exposure to the agent and delivers a higher concentration of the agent to the cell. The methods and principals of bioconjugating CPNPs are taught by examples of bioconjugation of targeting molecules for breast cancer, pancreatic cancer, and leukemia.

摘要翻译： 非聚集的可再吸收的磷酸钙纳米粒子（CPNP）被生物缀合成靶向特定细胞特异性的分子。 CPNPs在正常生理pH下是稳定的颗粒。 化疗和成像剂可以与CPNP整体形成，使得它们在CPNP内被分隔。 以这种方式，保护试剂免于在正常生理pH下与环境的相互作用。 然而，一旦CPNP被摄取，在细胞内的pH值下，CPNP溶解释放药剂。 因此，化学治疗或显像剂被递送到特定的细胞并允许这些细胞的治疗和/或成像。 使用生物共轭CPNP都限制了全身暴露于药剂的量，并将更高浓度的药剂递送至细胞。 生物缀合CPNP的方法和原理通过乳腺癌，胰腺癌和白血病靶向分子的生物缀合的实例来教导。

公开(公告)号：US09562095B2

公开(公告)日：2017-02-07

申请号：US14474284

申请日：2014-09-01

申请人： Jill P. Smith

发明人： Jill P. Smith

IPC分类号： C07K16/28 ,  A61K39/395 ,  C07K16/30 ,  A61K45/06 ,  G01N33/574

CPC分类号： C07K16/28 ,  A61K39/3955 ,  A61K45/06 ,  C07K16/2869 ,  C07K16/303 ,  C07K2317/11 ,  C07K2317/33 ,  C07K2317/34 ,  G01N33/57438 ,  G01N33/57446 ,  G01N2333/72

摘要： Human pancreatic cancer cells possess a distinct plasma membrane CCK receptor variant that can be differentiated from the classic CCK-B receptor with selective monoclonal antibodies. Use of this receptor may be helpful in early detection or treatment of patients with pancreatic cancer.

摘要翻译： 人胰腺癌细胞具有独特的质膜CCK受体变体，其可以与选择性单克隆抗体与经典的CCK-B受体区分开来。 使用此受体可能有助于早期检测或治疗胰腺癌患者。

公开(公告)号：US08821872B2

公开(公告)日：2014-09-02

申请号：US12772758

申请日：2010-05-03

申请人： Jill P. Smith ,  Gail L. Matters ,  Neil D. Christensen ,  John F. Harms

发明人： Jill P. Smith ,  Gail L. Matters ,  Neil D. Christensen ,  John F. Harms

IPC分类号： A61K39/395 ,  G01N33/53 ,  C07K16/30 ,  C12P21/08 ,  B82Y5/00

CPC分类号： G01N33/57438 ,  C07K16/2869 ,  C07K2317/33 ,  C07K2317/34 ,  G01N33/57446 ,  G01N2333/72

摘要： Human pancreatic cancer cells possess a distinct plasma membrane CCK receptor variant that can be differentiated from the classic CCK-B receptor with selective monoclonal antibodies. Use of this receptor may be helpful in early detection or treatment of patients with pancreatic cancer.

摘要翻译： 人胰腺癌细胞具有独特的质膜CCK受体变体，其可以与选择性单克隆抗体与经典的CCK-B受体区分开来。 使用此受体可能有助于早期检测或治疗胰腺癌患者。

公开(公告)号：US08889640B1

公开(公告)日：2014-11-18

申请号：US12489334

申请日：2009-06-22

申请人： Jill P. Smith ,  Mark Kester ,  Gail L. Matters ,  John F. Harms

发明人： Jill P. Smith ,  Mark Kester ,  Gail L. Matters ,  John F. Harms

IPC分类号： C12N15/11

CPC分类号： C12N15/1136 ,  C12N2310/14

摘要： Gastrin mRNA down-regulation using either stable transfection of an antisense gastrin cDNA or one of three shRNA (short hairpin RNA) constructs achieves significant reduction in growth of human pancreatic cancer. Tumor growth rate and incidence of metastases in both wild type and transfected pancreatic cancer cells is directly proportional to the degrees of gastrin mRNA expression. In order to avoid rapid degradation of injected siRNA, nanoliposomes can be loaded with gastrin siRNA and used to deliver the siRNA to the tumors. Significant reduction of tumors in mice using siRNA loaded nanoliposomes is achieved. Uptake of pegylated nanoliposomes by tumor cells depends upon the pegylation percentage.

摘要翻译： 使用稳定转染反义胃泌素cDNA或三种shRNA（短发夹RNA）构建体之一的胃泌素mRNA下调可显着降低人胰腺癌的生长。 野生型和转染的胰腺癌细胞的肿瘤生长速度和转移发生率与胃泌素mRNA表达程度成正比。 为了避免注射的siRNA的快速降解，纳豆脂质体可以加载胃泌素siRNA，并用于将siRNA递送至肿瘤。 实现使用siRNA负载纳米脂质体的小鼠肿瘤的显着减少。 肿瘤细胞对聚乙二醇化纳米脂质体的摄取取决于聚乙二醇化百分比。